In addition, antiangiogenic agents can reduce immunosuppression via the following mechanisms: restriction of Tregs chemotaxis and accumulation into tumors by suppressing the expression of IL-1β, IL-6, and CXCL1 (72), and alleviation of hypoxia through the normalization of the tumor vasculature relieving the immunosuppression exerted by TAMs, MDSCs, and Tregs (73) (Figure 2). Here, IL1B is linked to neoplasm.